Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atrasentan in pediatric primary IgA nephropathy
2025-522824-29-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of atrasentan in IgA nephropathy (IgAN), sponsored by Novartis. Primary endpoint: Change in proteinuria from baseline to Week 36 (all cohorts combined). Planned start Oct 2026; status: authorised.
02
Drugs
atrasentan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2025-522824-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522824-29-00.